Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S. Gordon

Showing results (71-80 of 202) with videos related to

Pageof 21
Sort By:
Future Oncology (London, England)|February 19, 2013
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancerJohn Marshall, Geoffrey I Shapiro, Martina Uttenreuther-Fischer, et al.
Substance Abuse|January 24, 2012
Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crimeJan Gryczynski, Timothy W Kinlock, Sharon M Kelly, et al.
Suicide & Life-Threatening Behavior|July 13, 2018
Evaluating the Feasibility and Effectiveness of an Australian Safety Planning Smartphone Application: A Pilot Study Within a Tertiary Mental Health ServiceGlenn A Melvin, Daniel Gresham, Susan Beaton, et al.
Journal of Addiction Medicine|January 31, 2025
A Naturalistic Study of Individuals Involved in the Justice System Who Experienced Both Formulations of Extended-release BuprenorphineThomas R Blue, Michael S Gordon, Frank J Vocci, et al.
Drug and Alcohol Dependence Reports|January 20, 2025
Extended-release buprenorphine induction in opioid non-tolerant incarcerated individualsMichael S Gordon, Thomas R Blue, Frank J Vocci, et al.
The American Journal of Drug and Alcohol Abuse|June 22, 2017
Avatar-assisted therapy: a proof-of-concept pilot study of a novel technology-based intervention to treat substance use disordersMichael S Gordon, Steven B Carswell, Mary Schadegg, et al.
Medical Teacher|July 16, 2005
Stroke training of prehospital providers: an example of simulation-enhanced blended learning and evaluationDavid Lee Gordon, S Barry Issenberg, Michael S Gordon, et al.
Anti-Cancer Drugs|February 3, 2015
Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumorsStephen Eppler, Michael S Gordon, Charles H Redfern, et al.
Drug and Alcohol Dependence|January 21, 2017
A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-releaseMichael S Gordon, Timothy W Kinlock, Robert P Schwartz, et al.
Cancer|October 22, 2008
A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancerMichael S Gordon, David Mendelson, Robert Carr, et al.
Pageof 21

Showing results (71-80 of 202) with videos related to

Sort By:
Pageof 21
Future Oncology (London, England)|February 19, 2013
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancerJohn Marshall, Geoffrey I Shapiro, Martina Uttenreuther-Fischer, et al.
Substance Abuse|January 24, 2012
Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crimeJan Gryczynski, Timothy W Kinlock, Sharon M Kelly, et al.
Suicide & Life-Threatening Behavior|July 13, 2018
Evaluating the Feasibility and Effectiveness of an Australian Safety Planning Smartphone Application: A Pilot Study Within a Tertiary Mental Health ServiceGlenn A Melvin, Daniel Gresham, Susan Beaton, et al.
Journal of Addiction Medicine|January 31, 2025
A Naturalistic Study of Individuals Involved in the Justice System Who Experienced Both Formulations of Extended-release BuprenorphineThomas R Blue, Michael S Gordon, Frank J Vocci, et al.
Drug and Alcohol Dependence Reports|January 20, 2025
Extended-release buprenorphine induction in opioid non-tolerant incarcerated individualsMichael S Gordon, Thomas R Blue, Frank J Vocci, et al.
The American Journal of Drug and Alcohol Abuse|June 22, 2017
Avatar-assisted therapy: a proof-of-concept pilot study of a novel technology-based intervention to treat substance use disordersMichael S Gordon, Steven B Carswell, Mary Schadegg, et al.
Medical Teacher|July 16, 2005
Stroke training of prehospital providers: an example of simulation-enhanced blended learning and evaluationDavid Lee Gordon, S Barry Issenberg, Michael S Gordon, et al.
Anti-Cancer Drugs|February 3, 2015
Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumorsStephen Eppler, Michael S Gordon, Charles H Redfern, et al.
Drug and Alcohol Dependence|January 21, 2017
A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-releaseMichael S Gordon, Timothy W Kinlock, Robert P Schwartz, et al.
Cancer|October 22, 2008
A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancerMichael S Gordon, David Mendelson, Robert Carr, et al.
Pageof 21